multiple myeloma
Conditions
Interventions
None listed
Sponsors
Kanazawa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with newly diagnosed MM who received induction regimens including bortezomib/ lenalidomide/ thalidomide prior to ASCT will be screened and analyzed. The patients receive high-dose melphalan (200 mg/sqm) plus ASCT in the hospitals of our research group and maintenance therapy using lenalidomide. MM is diagnosed according to the IMWG criteria, and the response of patients to therapy is assessed using the International Uniform Response Criteria. The response of patients must be CR or stringent CR (sCR) on days 100-365 post-ASCT. The diagnostic samples which include frozen BM cells/BM aspirate smear slide samples/BM non-decalcified clot samples must be obtained for the MRD analysis using NGS.
Exclusion criteria
Exclusion criteria: The patients who the physicians in charge judge to be inappropriate to participate in this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The correlation of MRD levels between BML-Flow and original EuroFlow methods. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) 1-year PFS post-ASCT and 3-year PFS post-ASCT 2) 1-year OS post-ASCT and 3-year OS post-ASCT 3) MRD negative rate in BM post-ASCT | — |
Countries
Japan
Contacts
Public ContactHiroyuki Takamatsu
Kanazawa University Department of Hematology
Outcome results
None listed